Geron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Geron and other ETFs, options, and stocks.

About GERN

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. 

CEO
Harout Semerjian
CEOHarout Semerjian
Employees
258
Employees258
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1990
Founded1990
Employees
258
Employees258

GERN Key Statistics

Market cap
1.07B
Market cap1.07B
Price-Earnings ratio
-12.90
Price-Earnings ratio-12.90
Dividend yield
Dividend yield
Average volume
22.12M
Average volume22.12M
High today
$1.69
High today$1.69
Low today
$1.56
Low today$1.56
Open price
$1.61
Open price$1.61
Volume
33.58M
Volume33.58M
52 Week high
$2.01
52 Week high$2.01
52 Week low
$1.04
52 Week low$1.04

Stock Snapshot

The current Geron(GERN) stock price is $1.65, with a market capitalization of 1.07B. The stock trades at a price-to-earnings (P/E) ratio of -12.90.

On 2026-04-03, Geron(GERN) stock moved within a range of $1.56 to $1.69. With shares now at $1.65, the stock is trading +5.7% above its intraday low and -2.4% below the session's peak.

Trading activity shows a volume of 33.58M, compared to an average daily volume of 22.12M.

Over the past 52 weeks, Geron(GERN) stock has traded between a high of $2.01 and a low of $1.04.

Over the past 52 weeks, Geron(GERN) stock has traded between a high of $2.01 and a low of $1.04.

GERN News

Simply Wall St 5d
Assessing Geron Valuation After Recent Share Price Weakness

Advertisement Event context and recent price performance With no specific news event flagged, Geron (GERN) has still been on investors’ radar after a 9.1% one...

Assessing Geron Valuation After Recent Share Price Weakness
Simply Wall St 7d
Geron Adds Biopharma Veterans As RYTELO Commercialization And Valuation Scrutinized

Geron Corporation (NasdaqGS:GERN) has appointed Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. Both appointees bring senior biopharm...

Geron Adds Biopharma Veterans As RYTELO Commercialization And Valuation Scrutinized

Analyst ratings

67%

of 6 ratings
Buy
66.7%
Hold
16.7%
Sell
16.7%

People also own

Based on the portfolios of people who own GERN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.